Organized screening has further improved outcomes by promoting earlier detection, while targeted treatments—including anti-HER2 agents, CDK4/6 inhibitors, and novel endocrine or immune therapies—have extended survival even in metastatic disease. Here, ERBB2 is linked to metastatic neoplasm.